AR053354A1 - Composicion de conjugado polisacarido neumococcico multivalente -proteina - Google Patents

Composicion de conjugado polisacarido neumococcico multivalente -proteina

Info

Publication number
AR053354A1
AR053354A1 ARP060101395A ARP060101395A AR053354A1 AR 053354 A1 AR053354 A1 AR 053354A1 AR P060101395 A ARP060101395 A AR P060101395A AR P060101395 A ARP060101395 A AR P060101395A AR 053354 A1 AR053354 A1 AR 053354A1
Authority
AR
Argentina
Prior art keywords
protein
conjugate
composition
polyaccocer
pneumococcico
Prior art date
Application number
ARP060101395A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36709976&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053354(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053354A1 publication Critical patent/AR053354A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composicion inmunogénica multivalente, que comprende: 13 conjugados polisacárido-proteína diferenciados y, optativamente, un adyuvante a base de aluminio. Cada conjugado contiene un polisacárido capsular de un serotipo diferente de Streptococcus pneumoniae (1, 3, 4, 5, 6 A, 6B, 7 F, 9V, 14, 18C, 19 A, 19F y 23F) conjugado a una proteína portadora. La composicion inmunogénica, formulada en forma de vacuna, aumenta la cobertura contra la enfermedad neumococica en lactantes y ninos pequenos en forma global, y confiere cobertura contra los serotipos 6 A y 19 A que no depende de las limitaciones de la proteccion cruzada entre serotipos.
ARP060101395A 2005-04-08 2006-04-07 Composicion de conjugado polisacarido neumococcico multivalente -proteina AR053354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66960505P 2005-04-08 2005-04-08

Publications (1)

Publication Number Publication Date
AR053354A1 true AR053354A1 (es) 2007-05-02

Family

ID=36709976

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101395A AR053354A1 (es) 2005-04-08 2006-04-07 Composicion de conjugado polisacarido neumococcico multivalente -proteina
ARP160103764A AR107018A2 (es) 2005-04-08 2016-12-07 Composición de conjugado polisacárido neomocóccico multivalente-proteína

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160103764A AR107018A2 (es) 2005-04-08 2016-12-07 Composición de conjugado polisacárido neomocóccico multivalente-proteína

Country Status (29)

Country Link
US (9) US20060228380A1 (es)
EP (9) EP2425853A1 (es)
JP (3) JP4472770B2 (es)
KR (11) KR101730749B1 (es)
CN (6) CN102716480B (es)
AR (2) AR053354A1 (es)
AT (1) ATE548051T1 (es)
AU (1) AU2006235013B2 (es)
BR (1) BRPI0607025B8 (es)
CA (4) CA2878579C (es)
CL (2) CL2016000566A1 (es)
CY (1) CY1112777T1 (es)
DK (1) DK1868645T3 (es)
ES (1) ES2382048T3 (es)
HK (3) HK1120416A1 (es)
HR (1) HRP20120278T1 (es)
IL (5) IL308456A (es)
ME (1) ME01334B (es)
MX (3) MX2007012336A (es)
MY (1) MY145150A (es)
NZ (1) NZ562406A (es)
PL (1) PL1868645T3 (es)
PT (1) PT1868645E (es)
RS (1) RS52249B (es)
SA (1) SA06270323B1 (es)
SI (1) SI1868645T1 (es)
TW (3) TWI386222B (es)
WO (1) WO2006110381A1 (es)
ZA (1) ZA200709483B (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
AU2012216628B9 (en) * 2006-04-26 2021-10-21 Wyeth Llc Novel Formulations which Stabilize and Inhibit Precipitation of Immunogenic Compositions
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
EP2155244B1 (en) * 2007-04-23 2017-03-22 Serum Institute of India Private Limited Antigenic polysaccharides and process for their preparation
EP2142211A1 (en) * 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccine
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009335824B2 (en) * 2008-12-18 2013-07-04 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon
KR20110091546A (ko) * 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
KR101315599B1 (ko) * 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
HUE041381T2 (hu) * 2012-08-16 2019-05-28 Pfizer Glikokonjugációs eljárások és kompozíciók
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
US9636392B2 (en) * 2012-09-07 2017-05-02 Sk Chemical Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104151426A (zh) * 2013-05-14 2014-11-19 北京天成新脉生物技术有限公司 肺炎链球菌十三种荚膜多糖单克隆抗体及其应用
CN103495161B (zh) * 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
PL3583947T3 (pl) 2014-01-21 2024-04-02 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2710393C2 (ru) 2014-01-21 2019-12-26 Пфайзер Инк. Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель
PL3096785T3 (pl) * 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
DK3313436T3 (da) 2015-06-23 2021-03-08 Biological E Ltd Multivalent pneumokok-konjugatvaccine
MY192183A (en) 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MY177587A (en) * 2015-09-10 2020-09-22 Inventprise Llc Multivalent vlp conjugates
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
SG11201900794PA (en) * 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101991457B1 (ko) * 2016-09-06 2019-09-30 주식회사 엘지화학 다가 협막 다당류-운반 단백질을 포함하는 조성물 및 이의 용도
EP3518965A1 (en) 2016-09-30 2019-08-07 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018126229A2 (en) * 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110198735A (zh) * 2017-01-20 2019-09-03 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
AU2018225083B2 (en) * 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
BR112019017560A2 (pt) 2017-02-24 2020-04-07 Merck Sharp & Dohme intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112019026192B1 (pt) 2017-06-10 2022-05-10 Inventprise, Llc Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
KR20200041311A (ko) 2017-06-23 2020-04-21 노소코미얼 백신 코포레이션 면역원성 조성물
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
MX2020002557A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11491216B2 (en) * 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112020021296A2 (pt) * 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo
EP3787674A4 (en) * 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
WO2019220304A1 (en) * 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
AU2019299836A1 (en) 2018-07-04 2021-02-25 Vaxcyte, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2021535921A (ja) * 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
JP2022525492A (ja) * 2018-10-12 2022-05-17 バイオロジカル イー リミテッド 多価肺炎球菌多糖類－タンパク質コンジュゲートワクチン
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
KR20220042378A (ko) 2019-07-31 2022-04-05 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
CN112741901B (zh) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
EP4090364A4 (en) * 2020-01-17 2024-02-21 Inventprise, Inc. MULTIVALENT STREPTOCOCCAL VACCINES
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
KR102610292B1 (ko) * 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CN114106210A (zh) * 2021-11-09 2022-03-01 北京智飞绿竹生物制药有限公司 一种23价肺炎球菌多糖疫苗的生产工艺
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024062494A1 (en) 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37741A (en) 1863-02-24 Improvement in bee-hives
US4097666A (en) * 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990010458A1 (en) 1989-03-09 1990-09-20 Praxis Biologics, Inc. Vaccines for nontypable haemophilus influenzae
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6221365B1 (en) 1996-07-26 2001-04-24 American Cyanamid Company NucA protein of Haemophilus influenzae
CA2274495C (en) 1996-12-20 2009-06-02 Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
ES2271987T3 (es) 1997-01-31 2007-04-16 Wyeth Holdings Corporation Proteina de 74 kilodalton de la membrana externa de moraxella catarrhalis.
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
DE69841676D1 (de) * 1997-12-23 2010-07-01 Baxter Healthcare Sa Verfahren zur extraktion und isolierung von bakteriellen hüllpolysacchariden zur verwendung als vakzine oder, an proteine gekoppelt, als konjugierte vakzine
WO1999040936A2 (en) * 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
IL142017A0 (en) * 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CA2370887A1 (en) 1999-06-25 2001-01-04 Benjamin J. Metcalf Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1296715E (pt) * 2000-06-29 2012-01-19 Smithkline Beecham Biolog Composição vacinal multivalente
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ATE267767T1 (de) * 2000-12-13 2004-06-15 Sca Hygiene Prod Zeist Bv Rückgewinnungsprozess für gebrauchtes periodat
ES2359625T3 (es) 2000-12-28 2011-05-25 Wyeth Llc Proteina protectora recombinante de.
JP2005501518A (ja) 2001-04-16 2005-01-20 ワイス・ホールディングズ・コーポレイション ポリペプチド抗原をコードしている新規ストレプトコッカスニューモニアエオープンリーディングフレームおよびその使用
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20050203280A1 (en) 2001-11-29 2005-09-15 Mcmichael John C. Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP2005532789A (ja) 2002-03-15 2005-11-04 ワイス・ホールデイングス・コーポレーシヨン 減少した酵素活性を有する型別不能なインフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａ）のＰ４タンパク質の変異体
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
WO2004026024A2 (en) * 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1618185A4 (en) 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
CN1241937C (zh) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 多价肺炎球菌多糖结合疫苗
CN100423774C (zh) * 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
US7582459B2 (en) * 2003-09-11 2009-09-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Process for producing a capsular polysaccharide for use in conjugate vaccines
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
TWI355390B (en) 2003-12-17 2012-01-01 Wyeth Llc Immunogenic peptide carrier conjugates and methods
US20060022838A1 (en) 2004-07-27 2006-02-02 Fisher Richard A Speed limit indicia for traffic signals
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) * 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
CN103223163A (zh) 2006-09-29 2013-07-31 财团法人日本小儿麻痹症研究所 Ipv-dpt疫苗
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2008340949A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
PL3096785T3 (pl) 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
BR112019017560A2 (pt) * 2017-02-24 2020-04-07 Merck Sharp & Dohme intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae

Also Published As

Publication number Publication date
CA2878579C (en) 2018-01-23
IL186367A0 (en) 2008-01-20
EP2425856A1 (en) 2012-03-07
CN113198013A (zh) 2021-08-03
CY1112777T1 (el) 2016-02-10
MY145150A (en) 2011-12-30
CN101180079B (zh) 2012-07-18
EP2425855A1 (en) 2012-03-07
CN108404126A (zh) 2018-08-17
US20190388537A1 (en) 2019-12-26
MX358148B (es) 2018-08-07
AR107018A2 (es) 2018-03-14
BRPI0607025A2 (pt) 2009-07-28
BRPI0607025B1 (pt) 2019-11-12
KR101298053B1 (ko) 2013-08-20
KR102564388B1 (ko) 2023-08-08
KR102611449B1 (ko) 2023-12-06
CA2986862A1 (en) 2006-10-19
EP2425851A1 (en) 2012-03-07
IL308456A (en) 2024-01-01
WO2006110381A1 (en) 2006-10-19
DK1868645T3 (da) 2012-04-10
KR101588939B1 (ko) 2016-01-26
CN113198012A (zh) 2021-08-03
TW200719911A (en) 2007-06-01
CL2016000566A1 (es) 2016-10-28
JP2008535838A (ja) 2008-09-04
EP1868645B1 (en) 2012-03-07
KR20150061021A (ko) 2015-06-03
EP2425854A1 (en) 2012-03-07
EP2425853A1 (en) 2012-03-07
CN101180079A (zh) 2008-05-14
HRP20120278T1 (hr) 2012-04-30
EP3311836A1 (en) 2018-04-25
TWI511739B (zh) 2015-12-11
AU2006235013A1 (en) 2006-10-19
CN102716480B (zh) 2023-03-21
KR20070118700A (ko) 2007-12-17
JP2013006881A (ja) 2013-01-10
KR102378962B1 (ko) 2022-03-28
US20090130137A1 (en) 2009-05-21
KR101730749B1 (ko) 2017-04-26
ME01334B (me) 2013-12-20
US9981035B2 (en) 2018-05-29
CN102716480A (zh) 2012-10-10
KR20150061018A (ko) 2015-06-03
CA2604363A1 (en) 2006-10-19
SA06270323B1 (ar) 2010-10-05
JP5730261B2 (ja) 2015-06-03
ES2382048T3 (es) 2012-06-04
US9399060B2 (en) 2016-07-26
KR20220042483A (ko) 2022-04-05
US20160158345A1 (en) 2016-06-09
KR20230118200A (ko) 2023-08-10
KR102220506B1 (ko) 2021-03-02
TWI386222B (zh) 2013-02-21
KR20150061020A (ko) 2015-06-03
CL2017002206A1 (es) 2018-03-23
AU2006235013B2 (en) 2011-11-03
US20120237542A1 (en) 2012-09-20
EP2425852A1 (en) 2012-03-07
IL267125A (en) 2019-08-29
HK1120416A1 (en) 2009-04-03
CA3165042A1 (en) 2006-10-19
SI1868645T1 (sl) 2012-04-30
BRPI0607025B8 (pt) 2021-05-25
KR20210022768A (ko) 2021-03-03
ZA200709483B (en) 2009-03-25
US8895024B2 (en) 2014-11-25
CN104815327A (zh) 2015-08-05
KR20190104241A (ko) 2019-09-06
JP5173920B2 (ja) 2013-04-03
MX2007012336A (es) 2007-11-21
TWI445545B (zh) 2014-07-21
EP1868645A1 (en) 2007-12-26
EP4005595A1 (en) 2022-06-01
RS52249B (en) 2012-10-31
US20210283247A1 (en) 2021-09-16
CN113198013B (zh) 2024-02-20
KR101730748B1 (ko) 2017-04-26
HK1213184A1 (zh) 2016-06-30
JP2009161567A (ja) 2009-07-23
US10716848B2 (en) 2020-07-21
US20140314805A1 (en) 2014-10-23
US11191830B2 (en) 2021-12-07
IL228035A0 (en) 2013-09-30
CA2986862C (en) 2022-09-27
KR101730750B1 (ko) 2017-04-26
US20200179508A1 (en) 2020-06-11
JP4472770B2 (ja) 2010-06-02
CA2878579A1 (en) 2006-10-19
HK1257962A1 (zh) 2019-11-01
PT1868645E (pt) 2012-05-17
MX2019008863A (es) 2019-09-13
IL282638A (en) 2021-06-30
KR20170086139A (ko) 2017-07-25
CN108404126B (zh) 2022-10-18
US10780160B2 (en) 2020-09-22
US8808708B2 (en) 2014-08-19
KR20130048262A (ko) 2013-05-09
KR20150061019A (ko) 2015-06-03
TW201438734A (zh) 2014-10-16
TW201212937A (en) 2012-04-01
IL267125B (en) 2021-05-31
IL186367A (en) 2013-09-30
NZ562406A (en) 2009-09-25
KR102017842B1 (ko) 2019-09-03
PL1868645T3 (pl) 2012-07-31
US20060228380A1 (en) 2006-10-12
ATE548051T1 (de) 2012-03-15
CA2604363C (en) 2015-06-16
US20180250390A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
AR053354A1 (es) Composicion de conjugado polisacarido neumococcico multivalente -proteina
AR116043A2 (es) Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente
CL2017001842A1 (es) Método para fabricar un conjugado inmunogenico que comprende polisacarido de streptococcus pneumoniae serotipo 3 enlazado en forma covalente a una proteína portadora (divisional de solicitud n°3782-2007).
MX2009006547A (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
AR058592A1 (es) Vacuna
BRPI0721136A8 (pt) conjugado imunogênico, polissacarídeos de streptococcus pneumoniae sorotipo 1, composição imunogênica multivalente e seus métodos de produção
RS54349B1 (en) VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES
AR112332A2 (es) Composición inmunogénica de streptococcus pneumoniae, kit, procedimiento
TH108545B (th) สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต

Legal Events

Date Code Title Description
FC Refusal